With Gilead Sciences Inc. stepping away from its exclusive option rights to casdatifan in treating cancer, Arcus Biosciences Inc. has decided to move on by pricing a $150 million common stock offering. Arcus said Gilead’s rights to the HIF-2a inhibitor, which just produced positive early phase data, had expired.

Biopharmas raising money in public or private financings, including: Aptose, Inflarx, Matinas, Moleculin, Oculis, Sarepta.

Biopharmas raising money in public or private financings, including: Atai, Edesa, Junevity, Mair, Newleos, Pulsesight, Roche.

Raising $94.2 million in gross proceeds, Aardvark Therapeutics Inc. became the fifth biopharma company to list on Nasdaq so far in 2025.

Biopharmas raising money in public or private financings, including: Abcuro, Aligos, Bioxodes.

Biopharmas raising money in public or private financings, including: Lixte, Sionna.

Biopharmas raising money in public or private financings, including: Alterity, Grace, Mustang.

Raising money to advance promising science is a constant struggle, bringing biopharma executive leadership together to learn about investment strategies in the opening session at the Biotechnology Innovation Organization’s CEO and Investor Conference in New York. “We’re bottoms-up investors. If we like the technology, we like the product, we think it’s going to work, we want to find a way to invest,” said Chris Garabedian, chairman and CEO of Xontogeny.

Biopharmas raising money in public or private financings, including: Aardvark, Ascentage, Jyong, Neuronetics, Palatin.